Last edition
News about "Galderma"
Galderma has received a Complete Response Letter from the US FDA for its RelabotulinumtoxinA Biologics License Application, with observations limited to manufacturing processes and analytical methods.
Galderma | 02/07/2026 | By News Bureau | 112
Galderma Wins FDA Approval for Restylane Contour for Temple Hollowing
FDA approves Galderma’s Restylane Contour for temple hollowing, expanding its use with natural-looking results lasting up to 18 months and high patient satisfaction.
Galderma | 24/03/2026 | By News Bureau | 102
Galderma Launches First OBT-Based Restylane Injectables in Japan
Galderma has launched Restylane Defyne and Restylane Refyne in Japan, marking the first authorization of hyaluronic acid injectables powered by its proprietary Optimal Balance Technology (OBT) in the country.
Galderma | 12/02/2026 | By Darshana | 177
Galderma to Spotlight Injectable Aesthetics Innovation at IMCAS 2026 with Ten Scientific Posters
Galderma, the pure-play dermatology category leader with operations in nearly 90 countries, will present ten scientific posters highlighting the latest advances across its injectable aesthetics portfolio at the International Master Course on Aging Science (IMCAS) 2026 World Congress, to be held in Paris, France, from January 29 to 31, 2026.
Galderma | 23/01/2026 | By Darshana | 363
L'Oreal to Double Its Equity Stake in Galderma as Strategic Partnership Deepens
Galderma Group AG, the pure-play leader in the dermatology category, announced that L’Oréal Groupe plans to increase its equity investment in the company by acquiring an additional 10 percent stake from Sunshine SwissCo GmbH, a consortium led by EQT, the Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. as the sellers.
Galderma | 09/12/2025 | By Darshana | 300
Galderma | 14/10/2022 | By Sudeep Soparkar | 880
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy